RxDoctor Payments Data

Trent Leavitt, DO

Internal Medicine · Las Vegas, NVNPI 1215341938

Payments from drug & device makers

$1,188in general payments, 2019–2025

Across 65 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$287
  • Pfizer$272
  • GSK$139
  • AstraZeneca$106
  • Exact Sciences$99
  • Lilly USA, LLC$77
  • plus $207 from 7 others

What the payments were for

  • Food & beverage$1,188100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,188 in reported general payments places this provider in the 75th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$74,495
Medicare patients
194
Services billed
729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$94,056
OzempicSemaglutide53$72,092
MounjaroTirzepatide42$62,421
JardianceEmpagliflozin35$48,879
XareltoRivaroxaban38$42,587
RybelsusSemaglutide15$39,736
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$27,604
TivicayDolutegravir Sodium12$27,521
DescovyEmtricitabine/Tenofov Alafenam12$26,850
MyrbetriqMirabegron21$23,349
EntrestoSacubitril/Valsartan12$20,823
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,410
SymbicortBudesonide/Formoterol Fumarate25$8,611
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$7,774
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$5,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$287$111,82868 claims
PfizerEliquis$272$94,05685 claims
Lilly USA, LLCMounjaro$77$62,42142 claims
Johnson & JohnsonXarelto$26$42,58738 claims
GSKTrelegy Ellipta$139$27,60415 claims
AstraZenecaBreztri Aerosphere, Symbicort$106$18,02140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →